Human Lipoprotein (a) Native

Human Lipoprotein(a) Native_x000D_ Catalog number: B2017012_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 280-700 kDa_x000D_ Supplied as: Solution_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: 2-8°C_x000D_ Keywords: Lipoprotein(a), Lp(a), LPA, Apolipoprotein(a), Apo(a)_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies J Am Coll Cardiol. 2017 Feb 14;69(6):692-711._x000D_ 2: Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60._x000D_ 3: Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, Wilson RJ, Boyce M, Ray KK, Cho L, Watts GF, Koren M, Turner T, Stroes ES, Melgaard C, Campion GV. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels JAMA. 2022 May 3;327(17):1679-1687._x000D_ 4: Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial JAMA. 2023 Dec 5;330(21):2075-2083._x000D_ 5: Momtazi-Borojeni AA, Katsiki N, Pirro M, Banach M, Rasadi KA, Sahebkar A. Dietary natural products as emerging lipoprotein(a)-lowering agents J Cell Physiol. 2019 Aug;234(8):12581-12594._x000D_ 6: Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, Florio M, Kassahun H, Melquist S, Varrieur T, Haldar SM, Sohn W, Wang H, Elliott-Davey M, Rock BM, Pei T, Homann O, Hellawell J, Watts GF. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) Nat Med. 2022 Jan;28(1):96-103._x000D_ 7: Kronenberg F. Lipoprotein(a) Handb Exp Pharmacol. 2022;270:201-232._x000D_ 8: Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Lp(a): a New Pathway to Target? Curr Atheroscler Rep. 2022 Nov;24(11):831-838._x000D_ 9: Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association J Clin Lipidol. 2019 May-Jun;13(3):374-392._x000D_ 10: Lacaze P, Bakshi A, Riaz M, Polekhina G, Owen A, Bhatia HS, Natarajan P, Wolfe R, Beilin L, Nicholls SJ, Watts GF, McNeil JJ, Tonkin AM, Tsimikas S. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes J Am Coll Cardiol. 2022 Oct 4;80(14):1287-1298. _x000D_ _x000D_ Products Related to Human Lipoprotein(a) Native can be found at Proteins

Catalog Number: B2017012 (50 µg)

0.15

2

0.5